In the current economic climate, early-stage research-focused biotech companies are suffering from a severe shortage of cash. Large pharmaceutical companies, with access to funds, are examining their R&D costs but need to maintain product pipelines as they teeter on the edge of patent cliffs. Could these unique circumstances represent new opportunities to share the financial risks in drug development?